Total Payments
$1.7M
2024 Payments
$350,486
Companies
44
Transactions
2,938
Medicare Patients
4,356
Medicare Billing
$906,889
Payment Breakdown by Category
Other$1.4M (79.5%)
Consulting$164,044 (9.5%)
Travel$141,733 (8.2%)
Food & Beverage$48,246 (2.8%)
Education$795.29 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.4M | 688 | 79.0% |
| Consulting Fee | $164,044 | 76 | 9.5% |
| Travel and Lodging | $141,733 | 701 | 8.2% |
| Food and Beverage | $48,246 | 1,449 | 2.8% |
| Compensation for serving as faculty or as a speaker for a medical education program | $4,000 | 1 | 0.2% |
| Honoraria | $3,680 | 4 | 0.2% |
| Education | $795.29 | 19 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | $439,676 | 430 | $0 (2024) |
| Neurocrine Biosciences, Inc. | $317,756 | 446 | $0 (2024) |
| Otsuka America Pharmaceutical, Inc. | $258,528 | 328 | $0 (2024) |
| Axsome Therapeutics, Inc. | $140,324 | 170 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $132,680 | 308 | $0 (2024) |
| ITI, Inc. | $74,561 | 100 | $0 (2023) |
| Alkermes, Inc. | $66,839 | 137 | $0 (2024) |
| Allergan, Inc. | $42,571 | 175 | $0 (2020) |
| Sunovion Pharmaceuticals Inc. | $37,380 | 164 | $0 (2020) |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $31,566 | 32 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $350,486 | 411 | Teva Pharmaceuticals USA, Inc. ($97,921) |
| 2023 | $352,109 | 447 | Axsome Therapeutics, Inc. ($84,980) |
| 2022 | $220,899 | 334 | Otsuka America Pharmaceutical, Inc. ($48,157) |
| 2021 | $161,102 | 318 | Teva Pharmaceuticals USA, Inc. ($54,686) |
| 2020 | $87,069 | 218 | Teva Pharmaceuticals USA, Inc. ($34,144) |
| 2019 | $186,586 | 358 | Neurocrine Biosciences, Inc. ($76,048) |
| 2018 | $266,703 | 527 | Neurocrine Biosciences, Inc. ($95,111) |
| 2017 | $103,353 | 325 | Sunovion Pharmaceuticals Inc. ($18,519) |
All Payment Transactions
2,938 individual payment records from CMS Open Payments — Page 1 of 118
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,560.00 | General |
| Category: Neuroscience | ||||||
| 12/23/2024 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Travel and Lodging | In-kind items and services | $574.20 | General |
| Category: Neuroscience | ||||||
| 12/19/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Food and Beverage | In-kind items and services | $17.85 | General |
| Category: Psychology/Psychiatric | ||||||
| 12/19/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $12.41 | General |
| Category: NEUROSCIENCE | ||||||
| 12/19/2024 | Alkermes, Inc. | LYBALVI (Drug), LYBALVI, LYBALVI | Food and Beverage | In-kind items and services | $11.63 | General |
| Category: CNS | ||||||
| 12/18/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,320.00 | General |
| Category: PSYCHIATRY | ||||||
| 12/18/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Travel and Lodging | In-kind items and services | $838.60 | General |
| Category: PSYCHIATRY | ||||||
| 12/18/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Travel and Lodging | Cash or cash equivalent | $196.31 | General |
| Category: PSYCHIATRY | ||||||
| 12/18/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $125.74 | General |
| Category: PSYCHIATRY | ||||||
| 12/18/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Travel and Lodging | Cash or cash equivalent | $86.96 | General |
| Category: PSYCHIATRY | ||||||
| 12/18/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Travel and Lodging | Cash or cash equivalent | $72.96 | General |
| Category: PSYCHIATRY | ||||||
| 12/18/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Travel and Lodging | Cash or cash equivalent | $60.00 | General |
| Category: PSYCHIATRY | ||||||
| 12/18/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Travel and Lodging | Cash or cash equivalent | $54.94 | General |
| Category: PSYCHIATRY | ||||||
| 12/18/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Travel and Lodging | Cash or cash equivalent | $53.99 | General |
| Category: PSYCHIATRY | ||||||
| 12/18/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Travel and Lodging | Cash or cash equivalent | $13.75 | General |
| Category: PSYCHIATRY | ||||||
| 12/18/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Travel and Lodging | Cash or cash equivalent | $9.38 | General |
| Category: PSYCHIATRY | ||||||
| 12/18/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Travel and Lodging | Cash or cash equivalent | $9.38 | General |
| Category: PSYCHIATRY | ||||||
| 12/17/2024 | Teva Pharmaceuticals USA, Inc. | UZEDY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,125.00 | General |
| Category: Neurology | ||||||
| 12/17/2024 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Food and Beverage | In-kind items and services | $143.93 | General |
| Category: Neuroscience | ||||||
| 12/17/2024 | Teva Pharmaceuticals USA, Inc. | UZEDY (Drug) | Travel and Lodging | Cash or cash equivalent | $46.90 | General |
| Category: Neurology | ||||||
| 12/17/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $23.05 | General |
| Category: NEUROSCIENCE | ||||||
| 12/17/2024 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Food and Beverage | In-kind items and services | $13.78 | General |
| Category: Neuroscience | ||||||
| 12/16/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,250.00 | General |
| Category: Neuropsychiatry | ||||||
| 12/16/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Travel and Lodging | In-kind items and services | $44.89 | General |
| Category: Neuropsychiatry | ||||||
| 12/16/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $18.35 | General |
| Category: Neuropsychiatry | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 789 | 2,139 | $459,234 | $166,245 |
| 2022 | 13 | 935 | 2,829 | $552,577 | $189,860 |
| 2021 | 15 | 1,231 | 3,800 | $754,055 | $265,305 |
| 2020 | 16 | 1,401 | 4,408 | $709,266 | $285,479 |
Total Patients
4,356
Total Services
13,176
Medicare Billing
$906,889
Procedure Codes
57
All Medicare Procedures & Services
57 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 90868 | Treatment using magnetic field to stimulate nerve cells in brain, subsequent delivery and management | Office | 2023 | 13 | 357 | $133,875 | $49,983 | 37.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 181 | 670 | $111,890 | $40,021 | 35.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 211 | 374 | $74,800 | $29,443 | 39.4% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 156 | 300 | $45,000 | $18,449 | 41.0% |
| 90870 | Therapy using electrical currents | Facility | 2023 | 30 | 168 | $40,992 | $12,607 | 30.8% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 59 | 61 | $19,215 | $5,231 | 27.2% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 37 | 54 | $10,800 | $4,273 | 39.6% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 30 | 74 | $11,412 | $2,756 | 24.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 32 | 40 | $6,000 | $1,885 | 31.4% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 24 | 25 | $3,650 | $1,573 | 43.1% |
| 96146 | Administration of psychological or neuropsychological test by single standardized instrument via electronic platform with automated result | Office | 2023 | 16 | 16 | $1,600 | $24.50 | 1.5% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 181 | 1,174 | $196,410 | $63,659 | 32.4% |
| 90868 | Treatment using magnetic field to stimulate nerve cells in brain, subsequent delivery and management | Office | 2022 | 13 | 256 | $96,000 | $34,871 | 36.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 177 | 345 | $69,000 | $28,374 | 41.1% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 164 | 300 | $45,000 | $16,617 | 36.9% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 93 | 107 | $34,045 | $10,153 | 29.8% |
| G0407 | Follow-up inpatient consultation, intermediate, physicians typically spend 25 minutes communicating with the patient via telehealth | Facility | 2022 | 39 | 134 | $22,630 | $7,392 | 32.7% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 53 | 83 | $16,600 | $7,329 | 44.2% |
| 90870 | Therapy using electrical currents | Facility | 2022 | 17 | 89 | $21,716 | $7,107 | 32.7% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 52 | 169 | $22,820 | $5,093 | 22.3% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 75 | 83 | $14,323 | $4,571 | 31.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 44 | 61 | $9,150 | $3,582 | 39.1% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 13 | 14 | $3,483 | $1,095 | 31.4% |
| 96146 | Administration of psychological or neuropsychological test by single standardized instrument via electronic platform with automated result | Office | 2022 | 14 | 14 | $1,400 | $15.15 | 1.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 207 | 1,564 | $261,236 | $84,642 | 32.4% |
About Dr. Matthew Berger, MD
Dr. Matthew Berger, MD is a Psychiatry healthcare provider based in Moosic, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/23/2005. The National Provider Identifier (NPI) number assigned to this provider is 1295718237.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Matthew Berger, MD has received a total of $1.7M in payments from pharmaceutical and medical device companies, with $350,486 received in 2024. These payments were reported across 2,938 transactions from 44 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.4M).
As a Medicare-enrolled provider, Berger has provided services to 4,356 Medicare beneficiaries, totaling 13,176 services with total Medicare billing of $906,889. Data is available for 4 years (2020–2023), covering 57 distinct procedure/service records.
Ad
Practice Information
- Specialty Psychiatry
- Location Moosic, PA
- Active Since 11/23/2005
- Last Updated 04/09/2021
- Taxonomy Code 2084P0800X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1295718237
Products in Payments
- INGREZZA (Drug) $317,756
- AUSTEDO (Drug) $287,547
- REXULTI (Drug) $258,389
- Auvelity (Drug) $140,301
- CAPLYTA (Drug) $106,127
- UZEDY (Drug) $103,759
- VRAYLAR (Drug) $66,096
- INVEGA SUSTENNA (Drug) $60,374
- LYBALVI (Drug) $50,404
- Austedo XR (Drug) $47,931
- SPRAVATO (Drug) $42,169
- LATUDA (Drug) $37,380
- Trintellix (Drug) $36,958
- INVEGA TRINZA (Drug) $30,138
- Dayvigo (Drug) $28,941
- FANAPT (Drug) $28,212
- QUVIVIQ (Drug) $17,700
- ARISTADA (Drug) $15,507
- NUEDEXTA (Drug) $13,393
- NUPLAZID (Drug) $10,898
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.